Ophthalmology Search
Ophthalmology Ophthalmology
primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
Drug Information

Indication: Decreased IOP in adult patients w/ open-angle glaucoma or ocular HTN for whom monotherapy provides insufficien...

Indication: Elevated IOP in ocular HTN or open-angle glaucoma.

Indication: Chronic open-angle glaucoma, ocular HTN.

Indication: Elevated IOP in patients w/ ocular HTN & open-angle glaucoma when concomitant therapy is appropriate.

Indication: Decrease of IOP in adults w/ open-angle glaucoma or ocular HTN who are insufficiently responsive to topical &b...

Indication: Elevated IOP in patients w/ ocular HTN or open-angle glaucoma.

Indication: Reduction of elevated IOP in patients w/ open-angle glaucoma, chronic angle closure glaucoma & ocular HTN;...

Indication: Reduction of IOP in patients w/ primary open-angle glaucoma or ocular HTN.

Indication: Reduction of IOP in patients w/ primary open-angle glaucoma or ocular HTN.

Indication: Elevated IOP in patients w/ ocular HTN or open-angle glaucoma.

1  /  3
1  /  3
Editor's Recommendations
Most Read Articles
Pharmacists’ town hall with Ministry of Health: Preliminary highlights
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Early rhBNP application lessens severity of reperfusion injury in PCI-treated STEMI patients
Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
Prophylactic methylprednisolone may benefit some neonates undergoing cardiac surgery
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
Poor lung function may predict future arterial stiffness
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.